At a glance
ClinicalIndex Comparison RecordN/ACompleted· 65 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Study to Define the Unique Molecular Mechanisms of Mitral Regurgitation in Order to Find New Targeted Therapy to Attenuate the Remodeling and Delay the Need for Surgery and Improve Surgical Outcomes.
In Brief
An observational study for Mitral Regurgitation. Completed, enrolled 65 participants across 1 site.
Detailed Summary
The investigators hypothesize that MR in humans is characterized by adrenergic overdrive, reactive nitrogen species, and an antifibrotic phenotype that relate to the severity of adverse LV remodeling prior to surgery and outcome after valve repair.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsMitral Regurgitation
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJun 2005
First PostedJan 2010
Primary CompletionNov 2010
TodayJul 2026
First PostedJan 20, 2010
Enrollment StartJun 1, 2005
Primary CompletionNov 1, 2010
TodayJul 2, 2026
Enrollment to primary: 5.4 yearsPosted 16.4 years ago